Aditxt, a social innovation platform, has entered into a custody agreement with Crypto.com to launch bitXbio, a crypto-native social platform that integrates biotech and fintech.
According to the terms of this new deal, Crypto.com will act as the custodian for Aditxt’s digital treasury. This support is crucial for Aditxt’s strategy to fund its biotech initiatives using a reserve of digital assets, such as Bitcoin. Additionally, Aditxt’s ADTX common stock can now be traded via Crypto.com’s broker-dealer service, providing greater convenience for both retail and institutional crypto investors.
Investment in bitXbio through Crypto.com Custody
Aditxt is dedicated to health advancements and supports a wide range of research institutions, partners, and shareholders. The company currently manages two key programs focused on precision health and immune health, with plans to introduce another program targeting women’s health.
Crypto.com Custody offers robust institutional-grade custody solutions for Aditxt. These services will enable eligible institutions and high-net-worth individuals to access these assets through a secure platform. The company believes that businesses across various sectors are increasingly considering financial asset treasuries, and its collaboration with Aditxt aims to engage crypto native traders.
bitXbio is an initiative designed to enhance public access to emerging technologies in immune reprogramming, early cancer detection, women’s health, and other critical areas. The agreement is seen as a pivotal step towards aligning Aditxt’s biotech assets with modern financial infrastructure. By harnessing Crypto.com’s custody features, the firm aims to create a platform where value generated through development can be easily accessible through digital finance.
The bitXbio initiative follows Aditxt’s proposed acquisition of Evofem under an Amended and Restated Merger Agreement. While the deal with Evofem is subject to certain conditions, both companies are actively working towards a potential closure in the second half of 2025.
